Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The development comes as stroke remains one of the world’s biggest health threats
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Subscribe To Our Newsletter & Stay Updated